Navidea Biopharmaceuticals (FRA:NO1A) Additional Paid-In Capital : €358.26 Mil(As of Sep. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Navidea Biopharmaceuticals Additional Paid-In Capital?

Navidea Biopharmaceuticals's quarterly additional paid-in capital declined from Mar. 2023 (€354.37 Mil) to Jun. 2023 (€352.85 Mil) but then increased from Jun. 2023 (€352.85 Mil) to Sep. 2023 (€358.26 Mil).

Navidea Biopharmaceuticals's annual additional paid-in capital increased from Dec. 2020 (€308.60 Mil) to Dec. 2021 (€327.86 Mil) and increased from Dec. 2021 (€327.86 Mil) to Dec. 2022 (€358.10 Mil).

Navidea Biopharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Navidea Biopharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Additional Paid-In Capital Chart

Navidea Biopharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

297.34

311.26

308.60

327.86

358.10

Navidea Biopharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Additional Paid-In Capital	Get a 7-Day Free Trial															383.13	358.10	354.37	352.85	358.26

Navidea Biopharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Navidea Biopharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Navidea Biopharmaceuticals (FRA:NO1A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (FRA:NO1A) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

NAVB:USA

Address

4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552

Website

https://www.navidea.com

Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.

Navidea Biopharmaceuticals (FRA:NO1A) Headlines

No Headlines